Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P, Lehmann-Che J, Varna M, Dumay A, Poirot B, Porcher R, Turpin E, Plassa LF, de Roquancourt A, Bourstyn E, de Cremoux P, Janin A, Giacchetti S, Espié M, de Thé H. Bertheau P, et al. Breast. 2013 Aug;22 Suppl 2:S27-9. doi: 10.1016/j.breast.2013.07.005. Breast. 2013. PMID: 24074787 Free article. Review.
p53 as an Effector or Inhibitor of Therapy Response.
Ablain J, Poirot B, Esnault C, Lehmann-Che J, de Thé H. Ablain J, et al. Cold Spring Harb Perspect Med. 2015 Dec 4;6(1):a026260. doi: 10.1101/cshperspect.a026260. Cold Spring Harb Perspect Med. 2015. PMID: 26637438 Free PMC article. Review.
Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer.
Groheux D, Biard L, Lehmann-Che J, Teixeira L, Bouhidel FA, Poirot B, Bertheau P, Merlet P, Espié M, Resche-Rigon M, Sotiriou C, de Cremoux P. Groheux D, et al. Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1279-1288. doi: 10.1007/s00259-018-3998-z. Epub 2018 Apr 4. Eur J Nucl Med Mol Imaging. 2018. PMID: 29616304
18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients.
de Cremoux P, Biard L, Poirot B, Bertheau P, Teixeira L, Lehmann-Che J, Bouhidel FA, Merlet P, Espié M, Resche-Rigon M, Sotiriou C, Groheux D. de Cremoux P, et al. Oncotarget. 2018 Mar 27;9(23):16343-16353. doi: 10.18632/oncotarget.24674. eCollection 2018 Mar 27. Oncotarget. 2018. PMID: 29662649 Free PMC article.
87 results